BioNTech’s second act: can it transform the fight against cancer?

It could transform the pharmaceutical industry. The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven. BioNTech founders Uğur Şahin and Özlem Türeci, who made the best-selling COVID-19 vaccine, want to use their new wealth to fuel an incredible venture: to tailor drugs to each patient’s cancer. Hanna Kuchler investigates.